The path to understanding and overcoming late-stage cancer begins with Intermountain Precision Genomics' ICG100 test, a personalized approach to cancer care.
Cancer is caused by changes in DNA that can make a normal cell become cancerous. Using ICG100 to figure out exactly what changes, or gene mutations, have happened in your body, we can personalize treatment specifically to your cancer.
Intermountain Precision Genomics' unique process analyzes the genetic makeup of a patient’s late-stage (stage IV) cancer by reading individual cancer genes and identifying abnormalities that we can then target in treatment.
Analysis and Personalized Results
Our experienced team of oncologists and cancer specialists collaborate to analyze and evaluate the results from our in-house, state-of-the-art laboratory.
ICG100 results can help providers recommend a plan of treatment tailored to the patient. This could include traditional therapy, infusions, or targeted drug therapies.
Options are often available in the form of highly personalized oral chemotherapeutic pills patients can take at home with fewer side-effects than traditional systemic chemotherapy. While not always curative, targeted therapeutics often result in additional quality time for patients.
Dedicated to Care
Together, Intermountain Precision Genomics and your trusted physician will work with you to determine your unique needs, communicate and review results with you, and develop a treatment plan just for you.
Qualifying Tests for Immunotherapy
MSI PCR Test
Usually ordered in combination with ICG100, the MSI PCR test can show whether or not DNA repair genes are functioning in your tumor, which affects how it will grow and how it should be treated. This test can lead you to more effective targeted therapies like immunotherapy, a personalized form of treatment that boosts the body’s own immune system to fight cancer.
PD-L1 is a protein that attaches to cells and tells them not to attack other cells. The presence of PD-L1 on a cancer cell can hide it from the body's natural defenses. Recent scientific developments now allow us to test for them. Performed in conjunction with ICG100, the PD-L1 test can identify these proteins in your body and qualify you as a candidate for immunotherapy, which can help to boost those defenses.